ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%
ENWEI PHARMACEUTICAL released its 2024 annual report, with operating revenue of 812 million yuan, a year-on-year increase of 3.43%; net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%; net profit excluding non-recurring gains and losses of 34.7296 million yuan, a year-on-year decrease of 52.80%; basic earnings per share of 0.3728 yuan/share. The company plans to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares
According to the Zhitong Finance APP, ENWEI PHARMACEUTICAL (301331.SZ) released its annual report for 2024, reporting an operating income of 812 million yuan for the year, a year-on-year increase of 3.43%; the net profit attributable to shareholders of the listed company was 37.4975 million yuan, a year-on-year decrease of 56.56%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 34.7296 million yuan, a year-on-year decrease of 52.80%; the basic earnings per share were 0.3728 yuan/share. It is proposed to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares
